SCHEMBL752211

SCHEMBL752211

O=C1CCc2cc(F)ccc2O1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH2 P05091 1/20 0.41
ALDH3A1 P30838 1/20 0.41
MAOB P27338 1/20 0.40
KDM4E B2RXH2 1/20 0.39
CYP1A2 P05177 1/20 0.39
GLA P06280 1/20 0.39
CYP2C9 P11712 1/20 0.39
HPGD P15428 1/20 0.39
CYP2C19 P33261 1/20 0.39
SIRT1 Q96EB6 1/20 0.39
HSD17B10 Q99714 1/20 0.39
SRD5A1 P18405 3/20 0.38
TSHR P16473 1/20 0.37
MLNR O43193 1/20 0.37
ADRB2 P07550 1/20 0.37
ADRB1 P08588 1/20 0.37
HTR1A P08908 1/20 0.37
ADRA2A P08913 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
CHRM1 P11229 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13950589 0.85 MAOB (0.50) ALDH2ALDH3A1MAOBKDM4ECYP1A2
SCHEMBL4290047 0.82 MAOA (0.45) MAOBFABP6
SCHEMBL28990338 0.82 PARP10 (0.49) MAOBHRH3PARP10
SCHEMBL32672830 0.77 ALDH2 (0.41) ALDH2ALDH3A1MAOBKDM4ECYP1A2
SCHEMBL3790824 0.77 HTR2A (0.37) KDM4ESRD5A1MLNRADRB2ADRB1
SCHEMBL28809160 0.77 DRD2 (0.37) SRD5A1MLNRADRB2ADRB1HTR1A
SCHEMBL4596158 0.77 AHR (0.43) ALDH2ALDH3A1KDM4ECYP1A2GLA
SCHEMBL5859179 0.77 ALDH2 (0.41) ALDH2ALDH3A1MAOBKDM4ECYP1A2
SCHEMBL3504905 0.77 ALDH2 (0.47) ALDH2ALDH3A1KDM4ECYP1A2GLA
SCHEMBL30749724 0.77 PTGS2 (0.51) ALDH2ALDH3A1MAOBKDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0111387-A1 Regeneration of 6-fluoro-4-chromanone from by-products in the synthesis of sorbinil PFIZER INC. (US) 1984-06-20 EP claimed
US-4431828-A Regeneration of 6-fluoro-4-chromanone from by-products in the synthesis of sorbinil PFIZER INC. (US) 1984-02-14 US claimed
EP-2220061-B1 SPIRO-CONDENSED 1, 3, 4-THIADIAZOLE DERIVATIVES FOR INHIBITING KSP KINESIN ACTIVITY MERCK SHARP & DOHME (US) 2016-02-17 EP disclosed
US-8796460-B2 Compounds for inhibiting KSP kinesin activity Mercky Sharp & Dohme Corp. (US) 2014-08-05 US disclosed
US-20120070370-A1 SPIRO 1,3,4-THIADIAZOLINE DERIVATIVES AS KSP INHIBITORS MERCK SHARP & DOHME CORP. 2012-03-22 US disclosed
EP-2430030-A1 SPIRO 1,3,4-THIADIAZOLINE DERIVATIVES AS KSP INHIBITORS Schering Corporation (US) 2012-03-21 EP disclosed
CN-102161653-A Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof ABBOTT LAB 2011-08-24 CN disclosed
US-20110171172-A1 COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY MERCK SHARP & DOHME CORP. 2011-07-14 US disclosed
US-20110123435-A1 COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY MERCK SHARP & DOHME LLC 2011-05-26 US disclosed
WO-2010132520-A1 SPIRO 1,3,4-THIADIAZOLINE DERIVATIVES AS KSP INHIBITORS SCHERING CORPORATION (US) 2010-11-18 WO disclosed
EP-2220061-A1 SPIRO-CONDENSED 1, 3, 4-THIADIAZOLE DERIVATIVES FOR INHIBITING KSP KINESIN ACTIVITY Schering Corporation (US) 2010-08-25 EP disclosed
US-4740517-A INHIBIT ALDOSE REDUCTASE SANWA KAGAKU KENYUSHO CO., LTD. (JP) 1988-04-26 US disclosed
CN-87100191-A The hydroxy acid derivative of treatment diabetic complication 1987-09-09 CN disclosed
EP-0193415-A2 Spiro-3-heteroazolidine compounds and salts thereof, their preparation and pharmaceutical agents thereof SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 1986-09-03 EP disclosed
EP-0185319-A2 Fluoro coumarins as antilymphoedema agents BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) 1986-06-25 EP disclosed
US-4528387-A Sorbinil by optical resolution of precursor 6-fluoro-4-ureidochroman-4-carboxylic acid PFIZER INC. (US) 1985-07-09 US disclosed
EP-0111387-A1 Regeneration of 6-fluoro-4-chromanone from by-products in the synthesis of sorbinil PFIZER INC. (US) 1984-06-20 EP disclosed
EP-0109231-A1 Sorbinil by optical resolution with aminopinane derivatives PFIZER INC. (US) 1984-05-23 EP disclosed
US-4435578-A Sorbinil by optical resolution of precursor 6-fluoro-4-ureidochroman-4-carboxylic acid PFIZER INC. (US) 1984-03-06 US disclosed
US-4431828-A Regeneration of 6-fluoro-4-chromanone from by-products in the synthesis of sorbinil PFIZER INC. (US) 1984-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120070370-A1 SPIRO 1,3,4-THIADIAZOLINE DERIVATIVES AS KSP INHIBITORS KIF2C, SKP1, KIF5B ALDH2 1529/4885ALDH3A1 898/4885MAOB 3994/4885
US-20110123435-A1 COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY KIF5B, KIF2C, KIFC1 ALDH2 2621/4885ALDH3A1 2236/4885MAOB 3462/4885
US-20110171172-A1 COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY KIF5B, KIF2C, KIFC1 ALDH2 2315/4885ALDH3A1 1887/4885MAOB 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.